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Abstract
Over the last months, due to coronavirus disease (COVID-19) pandemic, containment measures have led to important social
restriction. Healthcare systems have faced a complete rearrangement of resources and spaces, with the creation of wards devoted
to COVID-19 patients. In this context, patients affected by chronic neurological diseases, such as amyotrophic lateral sclerosis
(ALS), are at risk to be lost at follow-up, leading to a higher risk of morbidity and mortality. Telemedicine may allow meet the
needs of these patients. In this commentary, we briefly discuss the digital tools to remotely monitor and manage ALS patients.
Focusing on detecting disease progression and preventing life-threatening conditions, we propose a toolset able to improve ALS
management during this unprecedented situation.
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Coronavirus disease 2019 (COVID-19) has been spreading
throughout the world, and, on 11th of March, the World
Health Organization declared it to be pandemic [1].
Healthcare systems have suddenly faced an enormous and
complete rearrangement of resources and spaces, with the
realization of wards entirely devoted to COVID-19 patients.
Most of visits for chronic diseases have been canceled, post-
poned, or converted to teleconsultations (remote consultations
between patients and clinicians) [2–4]. In the next months, this
situation will probably persist. In this context, patients affect-
ed by chronic neurological diseases, such as amyotrophic lat-
eral sclerosis (ALS), are at risk of being lost at follow-up with
a consequently higher morbidity and mortality.
ALS is a neuromuscular progressive disorder, character-
ized by limb and bulbar muscle wasting and weakness.
Thirty percent of patients present a bulbar onset, while 70%
a spinal onset, although most of them develop bulbar impair-
ment during the course of the disease [5]. Nowadays, there is
still no curative treatment for ALS, and palliative care and
symptomatic treatment are therefore essential components in
the management of these patients. Death occurs in 3–5 years,
generally due to respiratory paralysis [5–7]. Neurological ex-
amination and ALS Functional Rating Scale revised
(ALSFRSr) are the most important tools to monitor disease
progression. Early detection of severe symptoms, such as dys-
phagia and respiratory impairment, reduces the risk of devel-
oping ab ingestis pneumonia and respiratory insufficiency,
improving the prognosis [8]. Therefore, it is important to es-
tablish an efficient service of telemedicine to replace face-to-
face visits, monitor progression of the disease, and manage
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complications as soon as possible [2], especially life-
threatening ones. Herein, we briefly review the available in-
struments to remotely manage ALS patients with the aim of
proposing a digital toolset (Fig.1) to face the current imposed
stay-home policy.
ALSFRSr is commonly used to evaluate ALS progression.
Some recent studies explored the possibility of an online self-
administered version of ALSFRSr scales [9, 10] reporting a
high inter-rater and intra-rater reproducibility, and a low var-
iability. Beyond ALSFRSr that can be easily compiled also by
phone calls, performing a neurological examination remotely
is also fundamental in the management of ALS. Recently, the
American Academy of Neurology (AAN) published recom-
mendations for improving a telemedicine service and sug-
gested tools to perform a general neurological examination
remotely [11]. Neurological examination through an audio-
video link showed good results in terms of reliability and
validity with bedside examination [12, 13], although with
some limitations in the assessment of muscle tone, vibration
sensation, and deep tendon reflexes.
In order to overcome limits intrinsic to remote neurological
examination, digital complementary tools have been pro-
posed. Some sensors were developed to objectively home-
monitoring ALS patients. Recent pivotal studies have investi-
gated the feasibility of wearable devices equipped with an
accelerometer for motor activity assessment and heart rate
variability detection [14]. Remotely monitoring invasive and
non-invasive ventilation through videoconferencing or home-
based self-monitoring has strong application in telemedicine
and in these patients could effectively reduce morbidity and
mortality [15]. Even bulbar function could be monitored in
remote, through the analysis of the recordings of patients read-
ing aloud a short paragraph, as Allison et al. reported [16].
They observed that the longitudinal evaluation of the percent-
age pause time expressed in seconds (a marker of speech
fluency) is one of the most important markers of pre-clinical
bulbar involvement in ALS. Another issue to be addressed is
the monitoring of the nutritional status, which is a relevant
prognostic factor. Countless nutrition-based mobile health
(mHealth) applications are available for both Android and
iOS. All are accessible and easy to use, but only few were
assessed in clinical studies. In a recent randomized trial com-
paring remote nutritional counseling with or without mobile
health technology in ALS patients, Nu Planit application was
an acceptable and useful mobile app to check nutritional status
[17]. It is a nutrition-based mHealth applications that facilitate
frequent reminders and measurements. Patients can record
their food habits and home weight measurements. Moreover,
based on patients’ gain or loss weight, the nutritionist could
remotely access to the app and modify dietary recommenda-
tion. In ALS evaluation of cognitive profile is important be-
cause around 30–50% of patients develop cognitive impair-
ment. A review highlighted the usefulness of some neuropsy-
chological test administered by videoconference in new diag-
nosis and in follow-up [18]. Unfortunately, only few cognitive
tests commonly used in ALS were tested, with a good agree-
ment between videoconference and in clinic neuropsycholog-
ical test. Receiving a diagnosis of a deadly illness such as ALS
can deeply affect the emotional, physical, and mental aspects
of a patients’ life, and in these patients, also the psychological
support is a key aspect of management. Transferring the meet-
ing with the psychologist on a digital platform could be useful
but not often accepted by the patients. Indeed, previous work
on multidisciplinary digital management of ALS patients
showed that psychological support was requested in few
cases, probably due to personal refusal, embarrassment, or
preference for a face-to-face contact [19].
All the issues debated point out the complexity of ALS
patients’management and the need to create multidisciplinary
teams able to face the new challenges due to this novel ap-
proach to patients’ care [20]. As discussed in detail by
Aghdam and colleagues, telemedicine offers a significant im-
provement in the organization of multidisciplinary teammeet-
ings compared with traditional settings. Indeed, it allows an
improved access to and collaboration of medical experts. This
results in an increased level of medical competence improving
diagnosis, treatment, and patients’ follow-up irrespective of
location [21]. In an ongoing project, De Marchi and col-
leagues theorized that satisfactorymultidisciplinary care could
be provided to ALS patients in their home using technology.
In this stay-home forced situation, they employed some of the
tools discussed above in order to prevent a greater decline of
the physical and psychological functions of ALS patients [22].











Nutrional status check with mobile app
Fig. 1 Digital tool set for ALS management in remote during COVID-19
pandemic
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aimed to detect, as soon as possible, how it can be useful to
avoid the postponed disease-related complications of this dev-
astating disease, trying to support patients and their caregivers
in the best way [22].
Overall, in our opinion, monitoring everyday life and po-
tential life-threatening aspects of the disease should be the
main goal of telemedicine in ALS patients, particularly at
the time of COVID-19 pandemic [23, 24]. As mentioned,
ALSFRSr and the neurological examination are the most im-
portant instruments to monitor disease status. Therefore, they
should be part of the set core of remote examination (Fig. 1)
and applied to all patients on follow-up teleconsultation.
While the digital assessment of motor functions through dig-
ital devices, such as accelerometer, is not reliable in a context
in which patients are forced to remain home, on the contrary,
speech analysis for bulbar function andmonitoring of invasive
and non-invasive ventilation could be crucial in reducingmor-
bidity and mortality and should be part of the set core. A study
of remote pulmonary function tests was conducted by the
Penn State Health Hershey ALS Center with patients, care-
givers, and respiratory therapists reporting high acceptability
[25]. Moreover, monitoring nutritional status through mHealth
applications is useful and accessible, and we suggest the use of
those apps for all ALS patients. A future perspective could be
the development of an app in order to achieve a complete self-
assessed evaluation of nutritional status, respiratory function,
motor ability, and subjective perceived health status, as was
already done for patients with Pompe disease [26].
The psychological support is very important especially im-
mediately after diagnosis for both patients and their relatives.
Remote psychological support could be essential in a period in
which hospital access has been reduced. Therefore, patients
and caregivers with psychological needs should receive the
opportunity for scheduled psychotherapy or on-demand calls
by a psychologist.
In a recent paper, Vasta and colleagues described their
experience of telemedicine with the management of ALS pa-
tients during the COVID-19 pandemic. In agreement with
previous studies, they revealed that patients reported to be
globally satisfied with respect to the telemedicine service they
received, but, despite the risk of contracting SARS-CoV2 in-
fection, most of them would have preferred an impatient visit.
Overall, the satisfaction of patients and caregivers for the use
of telemedicine is good, although face-to-face visits are still
largely preferred. Thus, telemedicine for ALS patients should
have a complementary and not a substitutive role, and it
should replace the in-person care depending on circumstances
and patient preferences [27].
Limitations in the use of those complementary tools in-
clude the high costs to acquire the instrumentation to be given
to patients, the training of patients’ and caregivers, and the
necessity of validation of some of these instrumentation and
tools administered by videoconference or self-administered.
In conclusion, implementing telemedicine services for pa-
tients with ALS is necessary to allow direct clinical evaluation
during COVID-19 pandemic, in order to plan the appropriate
medical and nursing care, avoiding hospitalizations or urgent
interventions.
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